Newsletters - February 2005

Newsletters - February 2005

In anticipation of the FDA's tightening regulations on dietary supplements, Sabinsa Corporation validated the safety and quality of its key nutraceutical ingredients, and the conformance of its facilities to current good manufacturing practices.

Proof of product purity and safety was obtained by submitting these ingredients to NSF International, the well established public health and safety organization. Gugulipid® 40 mesh 2.5 percent extract, Curcumin C3 Complex®, Tribulus terrestris 20 percent extract, Indole-3-Carbinol and Triphala extract were some of the ingredients tested. Sabinsa's facilities were also audited by NSF for conformance to current good manufacturing practices.

As summarized by Todd Norton , President of Sabinsa Corporation:

"We felt it important to take a proactive stance and work directly with an independent third-party, and in cooperation with our customers, to ensure our ingredients comply to the highest industry safety standards."

The FDA published draft guidelines on the current good manufacturing practice requirements for dietary supplements in March 2003, and is currently reviewing comments from the industry. FDA is also working on introducing a regulatory strategy for dietary supplements with an increased emphasis on safety.

    VISIT US

  • Sabinsa Europe GmbH
    Monzastrasse 4
    63225 Langen
    Germany

  • +49 6103 270 11 11
  • +49 6103 270 11 27
  • info@sabinsa.eu

CERTIFICATES

Certificate Logos Certificate Logos
Certificate Logos Certificate Logos

CONTACT US

Disclaimer

Please note that this website and information provided herein is not for final consumers of a finished food, beverage, dietary supplement product or cosmetic product, as the information contained herein does not refer to finished products for consumers.

The information provided on the website is intended only for producers of finished food, beverage, dietary supplement and cosmetic product.

The statements related to ingredients on the website, have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease.

The website and information herein are available in various countries across the world, and hence statements or product information including its classification may not be applicable in your country.

Information and statements provided on the website, shall not be construed as license to practice, or recommendations to infringe, any patents or other intellectual property rights of Sabinsa and others.

By browsing further, You understand the above terms.